Research Site
Zrenjanin 23000
1 studies enrolling now · 2 studies all time
What they study most
Breast Cancer, Early Breast Cancer
Studies at this site
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
— Recruiting now
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
— Recruiting now